Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.
Neurogastroenterol Motil. 2011 May;23(5):391-8. doi: 10.1111/j.1365-2982.2011.01689.x.
Stemming from the centuries-old and well known effects of Cannabis on intestinal motility and secretion, research on the role of the endocannabinoid system in gut function and dysfunction has received ever increasing attention since the discovery of the cannabinoid receptors and their endogenous ligands, the endocannabinoids. In this article, some of the most recent developments in this field are discussed, with particular emphasis on new data, most of which are published in Neurogastroenterology & Motility, on the potential tonic endocannabinoid control of intestinal motility, the function of cannabinoid type-1 (CB1) receptors in gastric function, visceral pain, inflammation and sepsis, the emerging role of cannabinoid type-2 (CB2) receptors in the gut, and the pharmacology of endocannabinoid-related molecules and plant cannabinoids not necessarily acting via cannabinoid CB1 and CB2 receptors. These novel data highlight the multi-faceted aspects of endocannabinoid function in the GI tract, support the feasibility of the future therapeutic exploitation of this signaling system for the treatment of GI disorders, and leave space for some intriguing new hypotheses on the role of endocannabinoids in the gut.
从大麻对肠道运动和分泌的几个世纪以来众所周知的作用中可以看出，自从发现大麻素受体及其内源性配体内源性大麻素以来，内源性大麻素系统在肠道功能和功能障碍中的作用的研究受到了越来越多的关注。本文讨论了该领域的一些最新进展，特别强调了关于肠道运动潜在的内源性大麻素控制的新数据，胃功能、内脏疼痛、炎症和败血症中大麻素 1 型（CB1）受体的功能、肠道中新型大麻素 2 型（CB2）受体的作用，以及内源性大麻素相关分子和植物大麻素的药理学，这些内源性大麻素相关分子和植物大麻素不一定通过大麻素 CB1 和 CB2 受体起作用。这些新数据突出了内源性大麻素在胃肠道中的多方面功能，支持未来对该信号系统治疗胃肠道疾病的治疗潜力进行探索，并为内源性大麻素在肠道中的作用提供了一些有趣的新假说。
